Lenzing Past Earnings Performance
Past criteria checks 0/6
Lenzing's earnings have been declining at an average annual rate of -74.4%, while the Chemicals industry saw earnings declining at 3.8% annually. Revenues have been growing at an average rate of 7.6% per year.
Key information
-74.4%
Earnings growth rate
-70.7%
EPS growth rate
| Chemicals Industry Growth | 4.3% |
| Revenue growth rate | 7.6% |
| Return on equity | -40.6% |
| Net Margin | -24.3% |
| Next Earnings Update | 14 Mar 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Lenzing makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2,614 | -636 | 447 | 26 |
| 30 Jun 24 | 2,582 | -616 | 434 | 26 |
| 31 Mar 24 | 2,556 | -601 | 419 | 24 |
| 31 Dec 23 | 2,521 | -649 | 416 | 21 |
| 30 Sep 23 | 2,461 | -279 | 400 | 27 |
| 30 Jun 23 | 2,522 | -240 | 407 | 25 |
| 31 Mar 23 | 2,574 | -177 | 424 | 26 |
| 31 Dec 22 | 2,566 | -73 | 424 | 29 |
| 30 Sep 22 | 2,576 | 68 | 417 | 26 |
| 30 Jun 22 | 2,455 | 92 | 400 | 27 |
| 31 Mar 22 | 2,320 | 105 | 376 | 26 |
| 31 Dec 21 | 2,195 | 110 | 352 | 24 |
| 30 Sep 21 | 2,026 | 109 | 317 | 22 |
| 30 Jun 21 | 1,856 | 86 | 281 | 19 |
| 31 Mar 21 | 1,656 | 12 | 251 | 17 |
| 31 Dec 20 | 1,633 | 6 | 245 | 16 |
| 30 Sep 20 | 1,702 | 3 | 291 | 12 |
| 30 Jun 20 | 1,860 | 46 | 336 | 9 |
| 31 Mar 20 | 2,058 | 101 | 376 | 5 |
| 31 Dec 19 | 2,162 | 123 | 407 | 0 |
| 30 Sep 19 | 2,210 | 132 | 407 | 0 |
| 30 Jun 19 | 2,240 | 136 | 404 | 0 |
| 31 Mar 19 | 2,236 | 143 | 399 | 0 |
| 31 Dec 18 | 2,232 | 149 | 389 | 0 |
| 30 Sep 18 | 2,222 | 197 | 383 | 0 |
| 30 Jun 18 | 2,240 | 222 | 376 | 0 |
| 31 Mar 18 | 2,275 | 255 | 369 | 0 |
| 31 Dec 17 | 2,305 | 278 | 364 | 0 |
| 30 Sep 17 | 2,318 | 282 | 355 | 0 |
| 30 Jun 17 | 2,278 | 280 | 349 | 0 |
| 31 Mar 17 | 2,232 | 255 | 341 | 0 |
| 31 Dec 16 | 2,156 | 225 | 331 | 0 |
| 30 Sep 16 | 2,123 | 200 | 332 | 0 |
| 30 Jun 16 | 2,084 | 167 | 318 | 0 |
| 31 Mar 16 | 2,044 | 153 | 316 | 0 |
| 31 Dec 15 | 2,006 | 127 | 317 | 0 |
| 30 Sep 15 | 1,991 | 28 | 301 | 0 |
| 30 Jun 15 | 1,944 | 24 | 306 | 0 |
| 31 Mar 15 | 1,915 | -3 | 303 | 0 |
| 31 Dec 14 | 1,899 | -13 | 301 | 0 |
| 30 Sep 14 | 1,895 | 11 | 319 | 0 |
| 30 Jun 14 | 1,901 | 2 | 323 | 0 |
| 31 Mar 14 | 1,924 | 18 | 323 | 0 |
| 31 Dec 13 | 1,948 | 31 | 326 | 0 |
Quality Earnings: 0NCV is currently unprofitable.
Growing Profit Margin: 0NCV is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0NCV is unprofitable, and losses have increased over the past 5 years at a rate of 74.4% per year.
Accelerating Growth: Unable to compare 0NCV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0NCV is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-36.8%).
Return on Equity
High ROE: 0NCV has a negative Return on Equity (-40.58%), as it is currently unprofitable.